Search
Search Results
-
ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression
ALK-positive ( +) large B cell lymphoma (ALK + LBCL) is a rare distinct subtype of diffuse large B cell lymphoma presenting with high stage and...
-
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
ALK and ROS1 fusions are effectively targeted by tyrosine kinase inhibitors (TKIs), however patients inevitably relapse after an initial response,...
-
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
BackgroundRandomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious...
-
Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
Anaplastic lymphoma kinase ( ALK ) gene fusion is a classic driver mutation in non-small cell lung cancer (NSCLC); however, ALK double-fusion variants...
-
Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis
Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and...
-
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
BackgroundAnaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKI; ALKi) have shown potent antitumor activity in metastatic non-small-cell...
-
ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature
ALK-rearranged renal cell carcinoma (ALK-RCC) is a very rare novel molecularly defined entity in the recently published fifth edition of the World...
-
New perspectives for targeting therapy in ALK-positive human cancers
Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor protein-tyrosine kinase superfamily and was first discovered in anaplastic...
-
Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
The single echinoderm microtubule-associated protein-like 4 ( EML4 ) gene and anaplastic lymphoma kinase ( ALK ) gene fusion is the most common variant...
-
Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor
Inflammatory myofibroblastic tumor (IMT), characterized by intermediate malignancy and a propensity for recurrence, has presented a formidable...
-
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Anaplastic lymphoma kinase ( ALK ) alterations (activating mutations, amplifications, and fusions/rearrangements) occur in ~3.3% of cancers. ALK ...
-
Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
BackgroundMalakoplakia is a rare inflammatory disease of the urogenital tract. There have been no reports of malakoplakia expressing anaplastic...
-
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
BackgroundThe acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK -rearranged NSCLC is associated with poor survival outcomes and...
-
Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK + anaplastic large cell lymphoma
Detection of ALK rearrangement and/or expression of the ALK protein is an essential component in the evaluation of many neoplasms. Variability has...
-
Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma
The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease....
-
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
The advent of next-generation sequencing (NGS) has allowed for the identification of novel therapeutic targets for patients with uncommon cancers. It...
-
Multisystem ALK-positive histiocytosis: a multi-case study and literature review
BackgroundAnaplastic lymphoma kinase (ALK)-positive histiocytosis, a novel rare histiocytic proliferation, was first described in 2008; it occurs in...
-
Long-term treatment with ALK inhibitors for postoperative recurrence of ALK-rearranged lung cancer
We encountered a 40-year-old female patient who developed, in chronological order, carcinomatous pleuritis and lymphangitis, multiple lymph node...
-
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
IntroductionAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard first- and second-line treatment for advanced ALK +...
-
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell...
